← Back to Sun Pharmaceutical Industries Ltd. overview
Sun Pharmaceutical Industries Ltd. — 10-Year Financials
Annual P&L, balance sheet, and key ratios from public BSE/NSE filings.
| Period | Revenue | Net Profit | EPS (₹) | Total Assets | Shareholder Equity | ROE (%) | ROCE (%) | D/E | Net Margin (%) |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | ₹52,041 cr | ₹10,929 cr | ₹45.6 | ₹92,101 cr | ₹72,218 cr | 15.13% | 18.75% | 0.03x | 21% |
| FY2024 | ₹47,758 cr | ₹9,576 cr | ₹39.9 | ₹85,500 cr | ₹63,667 cr | 15.04% | 16.92% | 0.05x | 20.05% |
| FY2023 | ₹43,279 cr | ₹8,474 cr | ₹35.3 | ₹80,744 cr | ₹55,995 cr | 15.13% | 15.24% | 0.12x | 19.58% |
| FY2022 | ₹38,426 cr | ₹3,273 cr | ₹13.6 | ₹69,800 cr | ₹48,011 cr | 6.82% | 9.35% | 0.03x | 8.52% |
Revenue: Total income from operations (₹ crore).
EPS: Earnings per share (₹), basic.
ROE: Net profit / average shareholder equity.
ROCE: EBIT / capital employed.
D/E: Total debt / shareholder equity.
Net Margin: Net profit as a % of revenue.
All figures sourced from public BSE/NSE filings. Ratios are pre-computed estimates and may differ from primary filings due to rounding.
Educational content — not investment adviceAll financial data is sourced from public filings and shown here for educational purposes only. EquitiesIndia.com is not a SEBI-registered Investment Adviser or Research Analyst. Nothing on this page constitutes a recommendation or solicitation to transact in any security. All data is at least 90 days old. Past performance is not indicative of future results.